Expand BDRX Menu
BDRX MENU

BDRX Latest Press Releases

-- March 10, 2025 --

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Globe Newswire 8:30 AM

-- March 6, 2025 --

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Globe Newswire 8:30 AM

-- February 24, 2025 --

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use Globe Newswire 8:30 AM

-- February 19, 2025 --

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now Globe Newswire 6:00 AM

-- February 18, 2025 --

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now Globe Newswire 7:00 AM

-- February 13, 2025 --

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Globe Newswire 8:30 AM

-- February 12, 2025 --

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status ACCESS Newswire 7:31 AM

-- February 10, 2025 --

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Globe Newswire 8:30 AM

-- January 22, 2025 --

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer Globe Newswire 8:30 AM

-- November 22, 2024 --

Result of General Meeting Globe Newswire 8:30 AM

-- November 21, 2024 --

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic ACCESSWIRE 7:36 AM

-- November 18, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX PRNewswire 9:12 PM

-- November 12, 2024 --

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Regains Compliance For Continued Listing on Nasdaq Globe Newswire 8:48 AM

-- November 7, 2024 --

Notice of General Meeting Globe Newswire 4:30 PM

-- November 2, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX PRNewswire 12:00 PM

-- October 29, 2024 --

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm Globe Newswire 4:00 PM

-- October 28, 2024 --

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm Business Wire 4:00 PM

-- October 27, 2024 --

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm PRNewswire 4:00 PM

-- October 25, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX PRNewswire 11:00 AM

-- October 23, 2024 --

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm Globe Newswire 4:00 PM

-- October 20, 2024 --

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm Business Wire 4:00 PM

-- October 17, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX PRNewswire 3:03 PM
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer ACCESSWIRE 7:31 AM

-- October 15, 2024 --

Biodexa Announces Successful Appeal of Nasdaq Delisting Globe Newswire 4:15 PM